Security Snapshot

FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) Institutional Ownership

CUSIP: 31189P102

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

143

Shares (Excl. Options)

72,009,393

Price

$0.98

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
FATE on Nasdaq
Shares outstanding
122,342,805
Price per share
$1.20
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
72,009,393
Total reported value
$70,808,357
% of total 13F portfolios
0%
Share change
-11,206
Value change
-$426,358
Number of holders
143
Price from insider filings
$1.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share is tracked under CUSIP 31189P102.
  • 143 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 143 to 17 between Q4 2025 and Q1 2026.
  • Reported value moved from $70,808,357 to $531,480.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 143 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 15% 0% $21,874,894 +$344,999 18,229,078 +1.6% Redmile Group, LLC 20 Apr 2026
BlackRock, Inc. 6.9% $10,600,447 7,852,183 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 2% -77% $2,546,902 -$6,958,784 2,274,020 -73% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Schonfeld Strategic Advisors LLC 0.82% -85% $1,050,024 -$7,679,831 937,521 -88% Schonfeld Strategic Advisors LLC 30 Jun 2025

As of 31 Dec 2025, 143 institutional investors reported holding 72,009,393 shares of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE). This represents 59% of the company’s total 122,342,805 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Redmile Group, LLC 11% 12,872,946 0% 0.93% $12,648,957
BlackRock, Inc. 8.3% 10,176,487 -4.7% 0% $9,999,415
VANGUARD GROUP INC 7.3% 8,971,347 +2% 0% $8,818,834
JOHNSON & JOHNSON 2.8% 3,379,064 0% 0.6% $3,320,268
ACADIAN ASSET MANAGEMENT LLC 2.4% 2,931,893 +8.2% 0% $2,878,000
GEODE CAPITAL MANAGEMENT, LLC 2% 2,468,348 -2.4% 0% $2,425,764
RENAISSANCE TECHNOLOGIES LLC 1.9% 2,360,881 +87% 0% $2,319,802
STATE STREET CORP 1.9% 2,265,217 -6.3% 0% $2,225,802
TWO SIGMA INVESTMENTS, LP 1.4% 1,734,064 +93% 0% $1,703,891
Vestal Point Capital, LP 1.4% 1,725,000 -31% 0.06% $1,694,985
TWO SIGMA ADVISERS, LP 1.4% 1,651,700 +64% 0% $1,622,960
DIMENSIONAL FUND ADVISORS LP 1.3% 1,577,478 -25% 0% $1,550,034
Point72 Asset Management, L.P. 1.2% 1,527,986 0% $1,501,399
GOLDMAN SACHS GROUP INC 1.2% 1,435,040 -3.5% 0% $1,410,070
TANG CAPITAL MANAGEMENT LLC 0.95% 1,167,773 -37% 0.06% $1,147,454
AQR CAPITAL MANAGEMENT LLC 0.95% 1,162,005 +2.7% 0% $1,141,787
MORGAN STANLEY 0.75% 916,946 -1.4% 0% $900,990
JANE STREET GROUP, LLC 0.69% 842,807 +40% 0% $828,142
Monaco Asset Management SAM 0.68% 830,000 +7.8% 0.24% $815,558
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.64% 784,628 -0.16% 0% $770,975
CITADEL ADVISORS LLC 0.61% 749,336 -9.1% 0% $736,298
NORTHERN TRUST CORP 0.6% 732,670 -10% 0% $719,921
Bruce & Co., Inc. 0.6% 729,188 0% 0.22% $716,500
DAFNA Capital Management LLC 0.45% 550,000 0.13% $540,430
MILLENNIUM MANAGEMENT LLC 0.43% 522,617 -46% 0% $513,523

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 439,898 $531,480 +$195,120 $1.20 17
2025 Q4 72,009,393 $70,808,357 -$426,358 $0.98 143
2025 Q3 80,446,666 $101,355,707 +$1,878,808 $1.26 138
2025 Q2 79,555,724 $88,833,451 -$17,593,195 $1.12 136
2025 Q1 96,451,503 $76,210,377 -$16,246,755 $0.79 127
2024 Q4 100,742,490 $166,216,764 -$49,322,737 $1.65 154
2024 Q3 114,626,757 $401,134,107 -$26,268,311 $3.50 157
2024 Q2 122,159,363 $400,671,566 -$37,762,295 $3.28 176
2024 Q1 122,980,750 $902,678,660 +$225,457,297 $7.34 160
2023 Q4 95,368,059 $356,677,597 -$5,241,221 $3.74 152
2023 Q3 95,698,313 $202,876,531 -$41,469,527 $2.12 164
2023 Q2 109,140,532 $519,540,682 -$18,388,551 $4.76 183
2023 Q1 112,556,300 $641,545,712 -$48,046,056 $5.70 177
2022 Q4 105,538,752 $1,064,884,147 -$72,227,908 $10.09 222
2022 Q3 107,847,419 $2,414,270,747 -$51,535,763 $22.41 226
2022 Q2 109,105,314 $2,682,160,938 +$198,082,382 $24.78 212
2022 Q1 101,146,307 $3,918,572,903 +$154,288,770 $38.77 235
2021 Q4 96,474,919 $5,644,897,783 +$10,118,846 $58.51 240
2021 Q3 95,702,027 $5,670,584,893 +$32,917,992 $59.27 254
2021 Q2 94,438,853 $8,194,463,579 +$63,508,082 $86.79 264
2021 Q1 93,763,343 $7,731,987,612 +$546,947,235 $82.45 251
2020 Q4 87,411,381 $7,948,482,716 -$84,784,180 $90.93 247
2020 Q3 87,813,890 $3,509,314,003 +$84,938,020 $39.97 210
2020 Q2 85,944,579 $2,946,905,994 +$357,311,792 $34.31 199
2020 Q1 75,606,763 $1,679,422,294 +$78,833,879 $22.21 153
2019 Q4 72,206,146 $1,413,058,139 -$18,741,577 $19.57 145
2019 Q3 73,759,772 $1,145,458,451 +$162,122,671 $15.53 147
2019 Q2 63,158,854 $1,282,170,068 +$56,656,459 $20.30 133
2019 Q1 60,804,461 $1,068,331,832 +$24,885,328 $17.57 121
2018 Q4 59,421,648 $762,327,973 +$32,572,198 $12.83 120
2018 Q3 54,832,749 $893,221,923 +$193,920,385 $16.29 116
2018 Q2 43,038,652 $488,060,307 +$35,286,017 $11.34 102
2018 Q1 39,404,544 $384,590,041 +$45,054,814 $9.76 87
2017 Q4 35,346,074 $215,961,575 +$67,123,779 $6.11 78
2017 Q3 25,410,496 $100,632,735 -$4,500,070 $3.96 71
2017 Q2 26,610,964 $86,219,950 +$4,849,002 $3.24 57
2017 Q1 25,029,354 $113,880,000 +$9,086,443 $4.55 51
2016 Q4 23,128,984 $57,885,000 +$7,405,875 $2.51 33
2016 Q3 19,481,982 $60,781,000 +$17,053,469 $3.12 36
2016 Q2 14,071,764 $23,921,000 -$3,087,760 $1.70 37
2016 Q1 15,773,542 $28,394,000 -$9,461,086 $1.80 42
2015 Q4 18,614,016 $62,724,000 -$726,308 $3.37 51
2015 Q3 18,349,000 $97,801,000 +$1,748,454 $5.33 41
2015 Q2 18,018,637 $116,577,000 +$48,004,684 $6.47 37
2015 Q1 10,608,782 $51,875,000 +$1,628,433 $4.89 25
2014 Q4 10,275,305 $51,680,000 -$3,435 $5.02 23
2014 Q3 10,270,522 $52,580,000 +$2,082,379 $5.10 22
2014 Q2 9,853,337 $62,410,000 +$1,716,802 $6.31 21
2014 Q1 9,563,610 $92,835,964 +$30,694,357 $9.74 21